Table 4 Comparison between the present study and the previous studies of LAHCC
Reference | Year | n | Treatment Method | OS |
|---|---|---|---|---|
Kudo M, et al. [3] | 2018 | 250 | Lenvatinib | Median OS: 11.5 months |
Bruix J, et al. [4] | 2012 | 108 | Sorafenib | Median OS: 8.1 months |
Yoon SM, et al. [5]) | 2018 | 45 | Sorafenib | Median OS: 9.9 months |
Kodama K, et al. [21] | 2018 | 36 | Sorafenib | Median OS: 5.3 months |
Kodama K, et al. [21] | 2018 | 36 | HAIC with RT | Median OS: 9.9 months |
Yoon SM, et al. [5] | 2018 | 45 | TACE with RT | Median OS: 12.7 months |
Zhang X, et al.a [22] | 2017 | 21–604 | Sorafenib | Median OS: 7.0–13.0 months |
Kudo M, et al. [15] | 2019 | 1101 | Surgery | 3y-OS: 40% |
Liu PH, et al. [23] | 2014 | 247 | Surgery | 3y-OS: 68% |
Shi J, et al. [24] | 2010 | 406 | Surgery | 3y-OS: 13% |
Komatsu S, et al. [25] | 2017 | 19 | Particle RT (proton beam therapy and C-ion RT) | Median OS: 24.6 months |
Present study | 11 | C-ion RT | Median OS: 36.4 months, 3y-OS: 64% |